Invention Grant
- Patent Title: Therapeutic uses of fibrinogen gamma prime variants
-
Application No.: US17212738Application Date: 2021-03-25
-
Publication No.: US11667694B2Publication Date: 2023-06-06
- Inventor: Miranda Weggeman , Joseph Grimbergen , Jacob Koopman
- Applicant: FIBRIANT B.V.
- Applicant Address: NL Leiden
- Assignee: FIBRIANT B.V.
- Current Assignee: FIBRIANT B.V.
- Current Assignee Address: NL Leiden
- Agency: One LLP
- Priority: EP 168993 2018.04.24 EP 168996 2018.04.24
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C07K14/75 ; A61P31/04 ; A61K9/00 ; A61K45/06

Abstract:
The present invention relates to compositions comprising fibrinogen gamma prime variants for use in the treatment or prevention of an infection and methods of administering the composition. The fibrinogen gamma prime variants in the composition comprise at least one fibrinogen gamma prime polypeptide chain. The compositions for use according to the invention may also comprise other fibrinogen variants. Compositions comprising fibrinogen gamma prime variants according to the invention improve survival time after infection up to more than 200 percent compared to WT fibrinogen. They may be used both therapeutically and prophylactically.
Public/Granted literature
- US20210347853A1 THERAPEUTIC USES OF FIBRINOGEN GAMMA PRIME VARIANTS Public/Granted day:2021-11-11
Information query
IPC分类: